These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19150935)

  • 1. Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer.
    Saeki T; Noguchi S; Aogi K; Inaji H; Tabei T; Ikeda T
    Ann Oncol; 2009 May; 20(5):868-73. PubMed ID: 19150935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer.
    Inaji H; Iwata H; Nakayama T; Yamamoto N; Sato Y; Tokuda Y; Aogi K; Saji S; Watanabe K; Saito T; Yoshida M; Sato N; Saeki T; Takatsuka Y; Kuranami M; Yamashita H; Kikuchi A; Tabei T; Ikeda T; Noguchi S
    Cancer Sci; 2012 Sep; 103(9):1708-13. PubMed ID: 22676245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability and pharmacokinetics of TAS-108, a novel anti-oestrogen, in healthy post-menopausal Japanese women: a phase I single oral dose study.
    Kumagai Y; Fujita T; Ozaki M; Yokota S; Maeda M; Shida M; Otani Y; Yamaya H; Tsuruta H
    Basic Clin Pharmacol Toxicol; 2009 May; 104(5):352-9. PubMed ID: 19175362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer.
    Blakely LJ; Buzdar A; Chang HY; Frye D; Theriault R; Valero V; Rivera E; Booser D; Kuritani J; Tsuda M
    Clin Cancer Res; 2004 Aug; 10(16):5425-31. PubMed ID: 15328180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer.
    Buzdar A; Vogel C; Schwartzberg L; Garin A; Perez A; Ingle J; Houghton M; Zergebel C; Kimball B
    Cancer; 2012 Jul; 118(13):3244-53. PubMed ID: 22045595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose.
    Yamaya H; Yoshida K; Kuritani J; Yonezawa J; Tsuda M; Shindo T; Nagayama S; Buzdar AU
    J Clin Pharm Ther; 2005 Oct; 30(5):459-70. PubMed ID: 16164493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients.
    Warm M; Kates R; Overkamp F; Thomas A; Harbeck N
    Breast Cancer Res Treat; 2011 Jan; 125(1):127-36. PubMed ID: 20960229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAS-108: a novel steroidal antiestrogen.
    Buzdar AU
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):906s-8s. PubMed ID: 15701885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K; Curran MP; Plosker GL
    Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
    Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
    J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.
    Robertson JF; Erikstein B; Osborne KC; Pippen J; Come SE; Parker LM; Gertler S; Harrison MP; Clarke DA
    Clin Pharmacokinet; 2004; 43(8):529-38. PubMed ID: 15170367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
    Yamamoto Y; Shibata J; Yonekura K; Sato K; Hashimoto A; Aoyagi Y; Wierzba K; Yano S; Asao T; Buzdar AU; Terada T
    Clin Cancer Res; 2005 Jan; 11(1):315-22. PubMed ID: 15671561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.
    James J; Murry DJ; Treston AM; Storniolo AM; Sledge GW; Sidor C; Miller KD
    Invest New Drugs; 2007 Feb; 25(1):41-8. PubMed ID: 16969706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulvestrant (Faslodex) -- how to make a good drug better.
    Robertson JF
    Oncologist; 2007 Jul; 12(7):774-84. PubMed ID: 17673609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study.
    Watanabe T; Sano M; Ohno S; Inaji H; Nishimura R; Shin E; Nomura Y; Morris C
    Anticancer Res; 2004; 24(2C):1275-80. PubMed ID: 15154660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
    Pritchard KI; Rolski J; Papai Z; Mauriac L; Cardoso F; Chang J; Panasci L; Ianuli C; Kahan Z; Fukase K; Lindemann JP; Macpherson MP; Neven P
    Breast Cancer Res Treat; 2010 Sep; 123(2):453-61. PubMed ID: 20632084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant revisited: efficacy and safety of the 500-mg dose.
    Howell A; Sapunar F
    Clin Breast Cancer; 2011 Aug; 11(4):204-10. PubMed ID: 21729658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer.
    Robertson JF; Odling-Smee W; Holcombe C; Kohlhardt SR; Harrison MP
    Clin Ther; 2003 May; 25(5):1440-52. PubMed ID: 12867220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.
    McCormack P; Sapunar F
    Clin Breast Cancer; 2008 Aug; 8(4):347-51. PubMed ID: 18757262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.